Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Compass Pathways's Total Liabilities for the quarter that ended in Jun. 2026 was $420.03 Mil. Compass Pathways's Total Assets for the quarter that ended in Jun. 2026 was $504.56 Mil.
Therefore, Compass Pathways's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2026 was 0.83.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Compass Pathways Liabilities-to-Assets Related Terms
Compass Pathways Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Compass Pathways's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMPS vs ARDT, HCSG, INNV: Liabilities-to-Assets Comparison
For the Medical Care Facilities subindustry, Compass Pathways's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Pathways Liabilities-to-Assets vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Compass Pathways's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Compass Pathways's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Pathways (CMPS) has a Liabilities-to-Assets of 0.83 as of Jun. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Compass Pathways and its competitors.
Is Compass Pathways' Liabilities-to-Assets too high?
Compass Pathways' current Liabilities-to-Assets is 0.83. Overall, Compass Pathways has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Compass Pathways' Liabilities-to-Assets compare to ARDT and HCSG?
Compass Pathways' Liabilities-to-Assets of 0.83 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Healthcare Providers & Services company?
A good Liabilities-to-Assets depends on the Healthcare Providers & Services industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Compass Pathways and its competitors. Compass Pathways's current Liabilities-to-Assets is 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Pathways stock overvalued right now?
Compass Pathways (CMPS) has a current Liabilities-to-Assets of 0.83. The current Liabilities-to-Assets is 0.83. Compass Pathways' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Compass Pathways (CMPS), the current Liabilities-to-Assets is 0.83 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
31GF Score
Get the complete analysis for CMPS
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMPS has been successfully added to your 
